Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser1177/Thr497 of endothelial nitric oxide synthase in diabetic mice

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Matsumoto, Sachiko ^a   Shimabukuro, Michio ^a   Fukuda, Daiju ^a   Soeki, Takeshi ^a   Yamakawa, Ken ^b   Masuzaki, Hiroaki ^b   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR; AZILSARTAN; CANDESARTAN HEXETIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAT; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; INFLAMMATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; VASCULAR ENDOTHELIUM; VASCULAR RING; VASCULITIS; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE III; ORGAN CULTURE TECHNIQUES; OXADIAZOLES; PHOSPHORYLATION; SERINE; THREONINE; VASCULITIS; VASODILATION;

EID: 84893161576     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-30     Document Type: Article

References (55)

1. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169. 10.1136/bmj.d4169, 3144314, 21791495.
2. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011, 364(9):829-841.
3. Investigators HOPEHS. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000, 355(9200):253-259.
4. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):1004-1010. 10.1016/S0140-6736(02)08090-X, 11937179.
5. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001, 88(9a):1l-20l.
6. Kumar R, Yong QC, Thomas CM, Baker KM. Intracardiac intracellular angiotensin system in diabetes. Am J Physiol Regul Integr Comp Physiol 2012, 302(5):R510-R517. 10.1152/ajpregu.00512.2011, 3311519, 22170614.
7. van der Zijl NJ, Moors CC, Goossens GH, Blaak EE, Diamant M. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms. Diabetes Obes Metab 2012, 14(7):586-595. 10.1111/j.1463-1326.2012.01559.x, 22226145.
8. Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease: From Marvel to Menace. Circulation 2006, 113(13):1708-1714. 10.1161/CIRCULATIONAHA.105.602532, 16585403.
9. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 2001, 88(2):E14-E22. 10.1161/01.RES.88.2.e14, 11157681.
10. Mount PF, Kemp BE, Power DA. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J Mol Cell Cardiol 2007, 42(2):271-279. 10.1016/j.yjmcc.2006.05.023, 16839566.
11. Imanishi T, Ikejima H, Tsujioka H, Kuroi A, Kobayashi K, Muragaki Y, Mochizuki S, Goto M, Yoshida K, Akasaka T. Addition of eplerenone to an angiotensin-converting enzyme inhibitor effectively improves nitric oxide bioavailability. Hypertension 2008, 51(3):734-741. 10.1161/HYPERTENSIONAHA.107.104299, 18227404.
12. Imanishi T, Tsujioka H, Ikejima H, Kuroi A, Takarada S, Kitabata H, Tanimoto T, Muragaki Y, Mochizuki S, Goto M, et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008, 52(3):563-572. 10.1161/HYPERTENSIONAHA.108.111120, 18645051.
13. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107(9):1058-1070. 10.1161/CIRCRESAHA.110.223545, 2996922, 21030723.
14. Sukumar P, Viswambharan H, Imrie H, Cubbon RM, Yuldasheva N, Gage M, Galloway S, Skromna A, Kandavelu P, Santos CX, et al. Nox2 NADPH oxidase has a critical role in insulin resistance-related endothelial cell dysfunction. Diabetes 2013, 62(6):2130-2134. 10.2337/db12-1294, 23349484.
15. Ago T, Kitazono T, Ooboshi H, Iyama T, Han YH, Takada J, Wakisaka M, Ibayashi S, Utsumi H, Iida M. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation 2004, 109(2):227-233. 10.1161/01.CIR.0000105680.92873.70, 14718399.
16. Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metab Clin Exp 2013, 62(11):1543-1552. 10.1016/j.metabol.2013.07.001, 23932846.
17. Lin HH, Stacey M, Stein-Streilein J, Gordon S. F4/80: the macrophage-specific adhesion-GPCR and its role in immunoregulation. Adv Exp Med Biol 2010, 706:149-156. 10.1007/978-1-4419-7913-1_13, 21618834.
18. Pelham CJ, Keen HL, Lentz SR, Sigmund CD. Dominant negative PPARγ promotes atherosclerosis, vascular dysfunction, and hypertension through distinct effects in endothelium and vascular muscle. Am J Physiol Regul Integr Comp Physiol 2013, 304(9):R690-R701. 10.1152/ajpregu.00607.2012, 23447133.
19. Sarfstein R, Werner H. Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction. Endocrinology 2013, 154(5):1672-1679. 10.1210/en.2012-2165, 23507573.
20. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, et al. Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int 2006, 70(10):1717-1724. 10.1038/sj.ki.5001810, 16985520.
21. Kurtz TW, Kajiya T. Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag 2012, 8:133-143. 3295635, 22399858.
22. Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharm Exp Ther 2011, 336(3):801-808.
23. Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K. Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 2013, 36(2):134-139. 10.1038/hr.2012.147, 23034464.
24. Flammer AJ, Anderson T, Celermajer DS, Creager MA, Deanfield J, Ganz P, Hamburg NM, Luscher TF, Shechter M, Taddei S, et al. The assessment of endothelial function: from research into clinical practice. Circulation 2012, 126(6):753-767. 10.1161/CIRCULATIONAHA.112.093245, 3427943, 22869857.
25. Zhang YH, Casadei B. Sub-cellular targeting of constitutive NOS in health and disease. J Mol Cell Cardiol 2012, 52(2):341-350. 10.1016/j.yjmcc.2011.09.006, 21945464.
26. Kolluru GK, Siamwala JH, Chatterjee S. eNOS phosphorylation in health and disease. Biochimie 2010, 92(9):1186-1198. 10.1016/j.biochi.2010.03.020, 20363286.
27. Yu F, Chen R, Takahashi T, Sumino H, Morimoto S, Nakahashi T, Iwai K, Matsumoto M, Kanda T. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin. Int J Cardiol 2008, 129(3):414-421. 10.1016/j.ijcard.2007.07.130, 18053594.
28. Chinen I, Shimabukuro M, Yamakawa K, Higa N, Matsuzaki T, Noguchi K, Ueda S, Sakanashi M, Takasu N. Vascular lipotoxicity: endothelial dysfunction via fatty-acid-induced reactive oxygen species overproduction in obese Zucker diabetic fatty rats. Endocrinology 2007, 148(1):160-165. 10.1210/en.2006-1132, 17023526.
29. Sonveaux P, Martinive P, DeWever J, Batova Z, Daneau G, Pelat M, Ghisdal P, Gregoire V, Dessy C, Balligand JL, et al. Caveolin-1 expression is critical for vascular endothelial growth factor-induced ischemic hindlimb collateralization and nitric oxide-mediated angiogenesis. Circ Res 2004, 95(2):154-161. 10.1161/01.RES.0000136344.27825.72, 15205364.
30. Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev 2013, 93(3):1317-1542. 10.1152/physrev.00004.2012, 23899566.
31. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 1996, 97(11):2601-2610. 10.1172/JCI118709, 507347, 8647954.
32. Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function: role of TNFα and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009, 29(8):1164-1171. 10.1161/ATVBAHA.109.187146, 2761384, 19478208.
33. Streit U, Reuter H, Bloch W, Wahlers T, Schwinger RH, Brixius K. Phosphorylation of myocardial eNOS is altered in patients suffering from type 2 diabetes. J Appl Physiol 2013, 114(10):1366-1374. 10.1152/japplphysiol.00011.2011, 23264539.
34. Mordwinkin NM, Meeks CJ, Jadhav SS, Espinoza T, Roda N, diZerega GS, Louie SG, Rodgers KE. Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow. Endocrinology 2012, 153(5):2189-2197. 10.1210/en.2011-2031, 3339643, 22434085.
35. Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. J Biol Chem 2001, 276(21):17625-17628. 10.1074/jbc.C100122200, 11292821.
36. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 2007, 87(1):245-313. 10.1152/physrev.00044.2005, 17237347.
37. Guzik TJ, Harrison DG. Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov Today 2006, 11(11-12):524-533.
38. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002, 105(14):1656-1662. 10.1161/01.CIR.0000012748.58444.08, 11940543.
39. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114(12):1752-1761. 10.1172/JCI21625, 535065, 15599400.
40. Meng D, Mei A, Liu J, Kang X, Shi X, Qian R, Chen S. NADPH oxidase 4 mediates insulin-stimulated HIF-1alpha and VEGF expression, and angiogenesis in vitro. PLoS One 2012, 7(10):e48393. 10.1371/journal.pone.0048393, 3483150, 23144758.
41. Patel H, Chen J, Das KC, Kavdia M. Hyperglycemia induces differential change in oxidative stress at gene expression and functional levels in HUVEC and HMVEC. Cardiovasc Diabetol 2013, 12(1):142. 10.1186/1475-2840-12-142, 3851327, 24093550.
42. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006, 24(1):11-25. 10.1097/01.hjh.0000191244.91314.9d, 16331093.
43. Sodhi CP, Kanwar YS, Sahai A. Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 2003, 284(3):H846-H852.
44. Oak JH, Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007, 56(1):118-126. 10.2337/db06-0288, 17192473.
45. Arun KH, Kaul CL, Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 2005, 65(2):374-386. 10.1016/j.cardiores.2004.10.010, 15639476.
46. Miura S, Karnik SS, Saku K. Angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst 2010, 12(1):1-7. 3891529, 20603272.
47. Nishida Y, Takahashi Y, Susa N, Kanou N, Nakayama T, Asai S. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study. Cardiovasc Diabetol 2013, 12(1):159. 10.1186/1475-2840-12-159, 24180232.
48. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharm Exp Ther 2007, 320(1):211-217.
49. Tiyerili V, Becher UM, Aksoy A, Lutjohann D, Wassmann S, Nickenig G, Mueller CF. AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARgamma. Cardiovasc Diabetol 2013, 12:30. 10.1186/1475-2840-12-30, 3667017, 23374104.
50. Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011, 29(12):2476-2483. 10.1097/HJH.0b013e32834c46fd, 21986624.
51. Takaoka M, Nagata D, Kihara S, Shimomura I, Kimura Y, Tabata Y, Saito Y, Nagai R, Sata M. Periadventitial adipose tissue plays a critical role in vascular remodeling. Circ Res 2009, 105(9):906-911. 10.1161/CIRCRESAHA.109.199653, 19762682.
52. Takaoka M, Suzuki H, Shioda S, Sekikawa K, Saito Y, Nagai R, Sata M. Endovascular injury induces rapid phenotypic changes in perivascular adipose tissue. Arterioscler Thromb Vasc Biol 2010, 30(8):1576-1582. 10.1161/ATVBAHA.110.207175, 20489168.
53. Shimabukuro M. Cardiac adiposity and global cardiometabolic risk: new concept and clinical implication. Circ J 2009, 73(1):27-34. 10.1253/circj.CJ-08-1012, 19057089.
54. Shimabukuro M, Kozuka C, Taira S, Yabiku K, Dagvasumberel M, Ishida M, Matsumoto S, Yagi S, Fukuda D, Yamakawa K, et al. Ectopic fat deposition and global cardiometabolic risk: new paradigm in cardiovascular medicine. J Med Invest 2013, 60(1-2):1-14.
55. Tarikuz Zaman AK, McLean DL, Sobel BE. The efficacy and tolerability of azilsartan in obese insulin-resistant mice with left ventricular pressure overload. J Cardiovasc Pharmacol 2013, 62(4):381-387. 10.1097/FJC.0b013e31829f0c1b, 23921308.